Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CAR T in patients with large B-cell lymphoma not fit for autologous transplant.
Kuhnl A, Kirkwood AA, Roddie C, Menne T, Tholouli E, Bloor A, Besley C, Chaganti S, Osborne W, Norman J, Gibb A, Sharplin K, Cuadrado M, Correia de Farias M, Cheok K, Neill L, Latif AL, González Arias C, Uttenthal B, Jones C, Johnson R, McMillan A, Sanderson R, Townsend W. Kuhnl A, et al. Among authors: cheok k. Br J Haematol. 2023 Jul;202(1):65-73. doi: 10.1111/bjh.18810. Epub 2023 Apr 20. Br J Haematol. 2023. PMID: 37082780
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma.
Roddie C, Neill L, Osborne W, Iyengar S, Tholouli E, Irvine D, Chaganti S, Besley C, Bloor A, Jones C, Uttenthal B, Johnson R, Sanderson R, Cheok K, Marzolini M, Townsend W, O'Reilly M, Kirkwood AA, Kuhnl A. Roddie C, et al. Among authors: cheok k. Blood Adv. 2023 Jun 27;7(12):2872-2883. doi: 10.1182/bloodadvances.2022009019. Blood Adv. 2023. PMID: 36724512 Free PMC article.
Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis.
Cheok KPL, Kirkwood AA, Menne T, Tholouli E, Chaganti S, Mathew A, Uttenthal B, Russell J, Irvine D, Johnson R, Nicholson E, Bazin J, Townsend W, Kuhnl A, O'Reilly M, Sanderson R, Patel A, Roddie C. Cheok KPL, et al. Leuk Lymphoma. 2022 Aug;63(8):1980-1984. doi: 10.1080/10428194.2022.2057487. Epub 2022 Apr 28. Leuk Lymphoma. 2022. PMID: 35481791 No abstract available.
Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis.
O'Reilly MA, Wilson W, Burns D, Kuhnl A, Seymour F, Uttenthal B, Besley C, Alajangi R, Creasey T, Paneesha S, Elliot J, Gonzalez Arias C, Iyengar S, Wilson MR, Delaney A, Rubio L, Lambert J, Begg K, Boyle S, Cheok KPL, Collins GP, Roddie C, Johnson R, Sanderson R. O'Reilly MA, et al. Among authors: cheok kpl. Hemasphere. 2024 Jun 13;8(6):e87. doi: 10.1002/hem3.87. eCollection 2024 Jun. Hemasphere. 2024. PMID: 38873532 Free PMC article.
High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma.
O'Reilly MA, Neill L, Collin SM, Stone N, Springell D, Mensah J, Cheok KPL, Jalowiec K, Benjamin R, Kuhnl A, Roddie C, Sanderson R. O'Reilly MA, et al. Among authors: cheok kpl. Hemasphere. 2024 Jan 26;8(1):e29. doi: 10.1002/hem3.29. eCollection 2024 Jan. Hemasphere. 2024. PMID: 38434533 Free PMC article.
Improved COVID-19 outcomes in CAR-T patients in the age of vaccination and preemptive pharmacotherapeutics.
Cheok KPL, Kirkwood AA, Creasey T, Tholouli E, Chaganti S, Mathew A, Dulobdas V, Irvine D, Besley C, Neil L, Lown R, Menne T, Townsend W, Kuhnl A, O'Reilly M, Sanderson R, Sanchez E, Roddie C. Cheok KPL, et al. Leuk Lymphoma. 2023 Dec;64(12):2037-2041. doi: 10.1080/10428194.2023.2248329. Epub 2023 Aug 21. Leuk Lymphoma. 2023. PMID: 37602678 No abstract available.
14 results